GL392

GL392 is a senolytic agent that selectively delivers the potent senolytic compound Dasatinib (HY-10181) to senescent cells. GL392 targets lipofuscin in senescent cells via the LBD domain and is linked to Dasatinib through an ester bond. Upon internalization in senescent cells, Dasatinib is released, inducing apoptosis of the senescent cells. Additionally, GL392 is encapsulated in PEO-b-PCL micelles to ensure effective intracellular delivery and minimize systemic toxicity. GL392 can be used in cancer research applications [1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis

Related Pathways

Apoptosis

Field of Research

Cancer

Smiles

CC1(COC(CCC(OCCN2CCN(C3=CC(NC4=NC=C(C(NC5=C(C)C=CC=C5Cl)=O)S4)=NC(C)=N3)CC2)=O)=O)NC6=CC=CC(C6=C(N1)C=C7)=C7/N=N/C(C=C8)=C9C(C=CC=C9)=C8/N=N/C%10=CC=CC=C%10

Molecular Formula

C55H52ClN13O5S

Molecular Weight

1042.60

References & Citations

[1]Magkouta S, et al. Generation of a selective senolytic platform using a micelle-encapsulated Sudan Black B conjugated analog. Nat Aging. 2025 Jan;5 (1) :162-175. doi: 10.1038/s43587-024-00747-4. Epub 2024 Dec 27. Erratum in: Nat Aging. 2025 Jan 31.